Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000721371
$255.64
-0.71% · live
Updated
$59.46B market value
From CARDINAL HEALTH INC's FY2026 10-K, filed Aug 11, 2026 · read the filing
CARDINAL HEALTH distributes goods wholesale to other businesses. It took in $254.25B last year, which makes it one of the largest companies in the world. Of every dollar it sells, about 1 cents is left as profit.
The financial picture is led by accounting, with profitability and growth worth watching, while debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score -0.22
Recent open-market selling by 7 insiders, not under a pre-arranged plan.
$59.6M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From CARDINAL HEALTH INC's FY2026 annual filing · share price scored separately
Largest year-over-year changes in FY2026
Free cash flow
$1.85B → $4.53B
Gross profit
$8.17B → $9.77B
Cash
$3.87B → $4.86B
Capital spending
$547.0M → $649.0M
Measured against FY2025, from the 10-K filed Aug 11, 2026
Improved: +144.6%
$1.85B to $4.53BCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
How the latest move compares (quote live), and what was published around it
CAH fell 0.71% on the latest quote. The S&P 500 moved −1.04%. That is in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 1% a year for the next 10 years. Over the last 10 years it grew by about 6% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 1 cents of every dollar of sales as profit, earning $1.71B last year.
Slowly. Sales grew 14.2% last year.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $0.95 in assets. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 29 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 9% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2026 annual filing
Last year it earned $1.71B and generated $5.17B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202610-K · Aug 11, 2026Filing for FY2026 | FY202510-K · Aug 12, 2025Filing for FY2025 | FY202410-K · Aug 14, 2024Filing for FY2024 | FY202310-K · Aug 14, 2024Filing for FY2023 | FY202210-K · Aug 14, 2024Filing for FY2022 | ChangeFY2026 vs FY2025 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | +14.2% |
| Cost of revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | +14.0% |
| Gross profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | +19.7% |
| Gross marginGross profit ÷ revenueWhat is this? | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | +0.2 pts |
| Selling, general and administrative | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | +13.9% |
| Operating income | $2.61B | $2.27B | $1.24B | $752.0M | -$607.0M | +14.9% |
| Operating marginOperating income ÷ revenueWhat is this? | 1.0% | 1.0% | 0.5% | 0.4% | -0.3% | +0.0 pts |
| Interest expense | $348.0M | $215.0M | $51.0M | $84.0M | $147.0M | +61.9% |
| Income before tax | $2.17B | $2.10B | $1.20B | $663.0M | -$784.0M | +3.5% |
| Net income | $1.71B | $1.56B | $852.0M | $330.0M | -$938.0M | +9.8% |
| Net marginNet income ÷ revenueWhat is this? | 0.7% | 0.7% | 0.4% | 0.2% | -0.5% | −0.0 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $7.37 | $6.54 | $3.49 | $1.32 | $-3.44 | +12.7% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| CAHCARDINAL HEALTH INC · this page | 6.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 2,500 shares at $234.57 ($586.4K)
Holds 19,480 shares after this filing.
Sold on the open market — 4,952 shares at $235.68 ($1.2M)
Holds 14,528 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingWrite down why you are following CARDINAL HEALTH INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 119 subsidiaries named in its 10-K, incorporated across 47 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from CAH's 10-K for fiscal year 2026 (period ending 2026-06-30, filed Aug 11, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2026 | 6.0 | 8/9 | 10-K, filed Aug 11, 2026 |
| FY2025 | 5.0 | 6/9 | 10-K, filed Aug 12, 2025 |
| FY2024 | 6.0 | 6/9 | 10-K, filed Aug 14, 2024 |
| FY2023 | 6.0 | 7/9 | 10-K, filed Aug 14, 2024 |
| FY2022 | 5.0 | 5/9 | 10-K, filed Aug 11, 2022 |
| FY2021 | 6.0 | 7/9 | 10-K, filed Aug 16, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
-0.22
In the distress zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.74
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Improved: +19.7%
$8.17B to $9.77BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +25.3%
$3.87B to $4.86BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +18.6%
$547.0M to $649.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +14.2%
$222.58B to $254.25BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +14.9%
$2.27B to $2.61BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +9.8%
$1.56B to $1.71BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +12.7%
$6.54 to $7.37Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -12.2%
$7.98B to $7.00BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: -2.6%
238.8M to 232.6MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between -1% and 3%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 23 analysts covering this company, as of . Their views, not this site's.
Of 23 analysts publishing on this company, 8 say strong buy, 12 say buy and 3 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 32.6x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 14.2% |
| 0.7% |
| 34.69x |
| -20.87x |
| MCKMCKESSON CORP | 6.0/10 | 6/9 | 12.4% | 1.2% | 25.55x | -38.90x |
|---|
| CORCencora, Inc. | 6.0/10 | 7/9 | 9.3% | 0.5% | 42.24x | 49.79x |
|---|
| Median of peers | 6.0/10 | — | 10.8% | 0.8% | 33.90x | 5.44x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 3,512 shares at $236.31 ($829.9K)
Holds 11,016 shares after this filing.
Sold on the open market — 686 shares at $237.25 ($162.8K)
Holds 10,330 shares after this filing.
Sold on the open market — 3,900 shares at $234.64 ($915.1K)
Holds 58,612 shares after this filing.
Sold on the open market — 10,246 shares at $235.51 ($2.4M)
Holds 48,366 shares after this filing.
Sold on the open market — 4,426 shares at $236.38 ($1.0M)
Holds 43,940 shares after this filing.
Sold on the open market — 10,864 shares at $237.31 ($2.6M)
Holds 33,076 shares after this filing.
Sold on the open market — 3,115 shares at $234.55 ($730.6K)
Holds 59,380 shares after this filing.
Sold on the open market — 12,228 shares at $235.54 ($2.9M)
Holds 47,152 shares after this filing.
Sold on the open market — 13,685 shares at $236.58 ($3.2M)
Holds 33,467 shares after this filing.
Sold on the open market — 12,972 shares at $237.26 ($3.1M)
Holds 20,495 shares after this filing.
Sold on the open market — 6,665 shares at $235.30 ($1.6M)
Holds 78,590 shares after this filing.
Sold on the open market — 408 shares at $236.59 ($96.5K)
Holds 78,182 shares after this filing.
Sold on the open market — 281 shares at $237.44 ($66.7K)
Holds 77,901 shares after this filing.
Sold on the open market — 3,100 shares at $234.59 ($727.2K)
Holds 49,961 shares after this filing.
Sold on the open market — 8,195 shares at $235.62 ($1.9M)
Holds 41,766 shares after this filing.
Sold on the open market — 10,876 shares at $236.50 ($2.6M)
Holds 30,890 shares after this filing.
Sold on the open market — 12,829 shares at $237.26 ($3.0M)
Holds 18,061 shares after this filing.
Sold on the open market — 21,407 shares at $234.56 ($5.0M)
Holds 293,725 shares after this filing.
Sold on the open market — 29,915 shares at $235.51 ($7.0M)
Holds 263,810 shares after this filing.
Sold on the open market — 16,208 shares at $236.54 ($3.8M)
Holds 247,602 shares after this filing.
Sold on the open market — 12,470 shares at $237.25 ($3.0M)
Holds 235,132 shares after this filing.
Sold on the open market — 6,206 shares at $233.22 ($1.4M)
Holds 228,926 shares after this filing.
Sold on the open market — 3,457 shares at $234.29 ($809.9K)
Holds 225,469 shares after this filing.
Sold on the open market — 5,704 shares at $235.34 ($1.3M)
Holds 219,765 shares after this filing.
Sold on the open market — 6,731 shares at $236.46 ($1.6M)
Holds 213,034 shares after this filing.
Sold on the open market — 16,187 shares at $237.23 ($3.8M)
Holds 196,847 shares after this filing.
Sold on the open market — 6,244 shares at $237.88 ($1.5M)
Holds 190,603 shares after this filing.
Sold on the open market — 100 shares at $237.40 ($23.7K)
Holds 5,013 shares after this filing.
Sold on the open market — 2,202 shares at $237.39 ($522.7K)
Holds 2,811 shares after this filing.
Was granted or awarded shares — 7,314 shares
Holds 115,014 shares after this filing.
Had shares withheld to cover taxes — 29,759 shares at $235.17 ($7.0M)
Holds 85,255 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 2,302 shares ($546.5K) on or after .
Shares originally obtained via Restricted Stock Vest.
Filed notice to sell 35,000 shares ($8.3M) on or after .
Shares originally obtained via Restricted Stock Vest.
Filed notice to sell 29,436 shares ($7.0M) on or after .
Shares originally obtained via Restricted Stock Vest.
Filed notice to sell 7,354 shares ($1.7M) on or after .
Shares originally obtained via Restricted Stock Vest.
Filed notice to sell 11,650 shares ($2.7M) on or after .
Shares originally obtained via Restricted Stock Vest.
Filed notice to sell 42,000 shares ($9.9M) on or after .
Shares originally obtained via Restricted Stock Vest.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Annual report for FY2026
Revenue +14.2% · Free cash flow +144.6% · Gross profit +19.7% — against FY2025
Published results · Made a Regulation FD disclosure
Read the filingSigned a material agreement · Terminated a material agreement · Took on a direct financial obligation
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report on Form 10-Q
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2026
Revenue +18.8% · Gross profit +23.5% · Operating income +28.8% — against Q2 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +22.4% · Free cash flow turned positive · Long-term debt +112.6% — against Q1 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingSigned a material agreement
Read the filingSigned a material agreement
Read the filingProxy statement for a shareholder meeting
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingThe first 40 of 119. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-08-11. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Yahoo ·
Should Upcoming Earnings Expectations Require Action From Cardinal Health Stock Investors?
Yahoo ·
Cardinal Health (CAH) Faces An Earnings Test On A Modestly Undervalued View
Yahoo ·
IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside
Yahoo ·
SpaceX earnings roundup, Meta earnings preview, and tech trade fears
Yahoo ·
Disposable Specimen Container Market Forecast Report 2026-2030 | Capitalize on Sterile Automation and $3.97B Demand with Leading Players Thermo Fisher, Cardinal Health, SARSTEDT and Greiner Bio-One
Yahoo ·
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo ·
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo ·
Cardinal Health (CAH) Laps the Stock Market: Here's Why
Yahoo ·
CII: Strong Recent Performance, But AI Exposure Could Trigger Losses
SeekingAlpha ·
Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $280
Benzinga ·
1 Profitable Stock Worth Investigating and 2 We Brush Off
Yahoo ·
Primary sources and further research